Here's Why Minerva Neurosciences Fell Over 28% Today
Shares of Minerva Neurosciences (NASDAQ: NERV) tumbled more than 28% today after the company provided an update on the status of three pipeline assets. The biggest news was that a phase 3 trial evaluating the company's lead drug candidate, MIN-101 (roluperidone), was delayed after a cyberattack on a contractor handling patient recruitment disrupted enrollment.
Minerva Neurosciences now expects the late-stage trial, studying MIN-101 as a potential treatment for negative symptoms of schizophrenia, to deliver top-line results in the first half of 2020. The results were originally expected before the end of 2019.
As of 2:10 p.m. EDT, the pharmaceutical stock had settled to a 26.8% loss.
Source Fool.com
